As of June 30, 2024, there were 493,970 shares available for issuance under the Myomo, Inc. 2018 Stock Option and Incentive Plan (the “2018 Plan”). On January 1 of each year, the number of shares of common stock reserved and available for issuance under the 2018 Plan will cumulatively increase by 4% of the number shares of common stock outstanding on the immediately preceding December 31 or such lesser number of shares of common stock determined by management in consultation with members of the Board of Directors, including the compensation committee of the Board of Directors. On January 1, 2024, 1,085,401 shares were added to the share reserve under the 2018 Plan.

Recipients of awards of restricted stock units typically sell shares in the open market to cover their individual tax liabilities and remit the proceeds to the Company, which offsets withholding taxes paid by the Company. In certain circumstances, stock awards may be net share settled upon vesting to cover the required employee statutory withholding taxes and the remaining amount is converted into shares based upon their share-value on the date the award vests. In such instances, these payments of employee withholding taxes are presented in the statements of cash flows as a financing activity. There were no stock awards that were net share settled during the three and six months ended June 30, 2024. There were 16,744 restricted stock units that were withheld as part of net share settlement transactions during the three and six months ended June 30, 2023.

The Company accounts for stock awards to employees and non-employees based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award.

The Company attributes the value of stock-based compensation to operations on the straight-line method such that the expense associated with awards is evenly recognized over the vesting period.

The Company recognized stock-based compensation expense related to the issuance of stock option awards and restricted stock units to employees, non-employees and directors in the statements of operations as follows:


	For the Three Months Ended					For the Six Months Ended
	June 30,					June 30,
	2024			2023		2024		2023
Cost of goods sold	$	(10,591	)	$	22,114	$	12,796	$	42,593
Research and development		8,719			34,308		32,964		(35,419	)
Selling, clinical and marketing		7,190			49,592		53,251		91,448
Selling, general and administrative		(97,211	)		174,047		129,384		352,466
Total	$	(91,893	)	$	280,061	$	228,395	$	451,088

As of June 30, 2024, there was approximately $13,300 of unrecognized compensation cost related to unvested stock options that is expected to be recognized over a weighted-average period of 0.97 years.

As of June 30, 2024, there was approximately $2,802,300 of unrecognized compensation expense related to unvested restricted stock units that is expected to be recognized over a weighted-average period of 2.66 years.